SEARCH:   Advanced

Blood, 15 April 2008, Vol. 111, No. 8, pp. 4297-4308. Prepublished online as a Blood First Edition Paper on January 11, 2008; DOI 10.1182/blood-2007-01-068346. This Article Full Text Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2007-01-068346v1 111/8/4297    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Watanabe-Okochi, N. Articles by Kitamura, T. PubMed PubMed Citation Articles by Watanabe-Okochi, N. Articles by Kitamura, T. Related Collections Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi1, Jiro Kitaura1, Ryoichi Ono1, Hironori Harada2, Yuka Harada3, Yukiko Komeno1, Hideaki Nakajima1, Tetsuya Nosaka1, Toshiya Inaba4, and Toshio Kitamura1 1 Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo; 2 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; 3 International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; and 4 Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan Myelodysplastic syndrome (MDS) is a hematopoietic stem-cell disorder characterized by trilineage dysplasia and susceptibility to acute myelogenous leukemia (AML). Analysis of molecular basis of MDS has been hampered by the heterogeneity of the disease. Recently, mutations of the transcription factor AML1/RUNX1 have been identified in 15% to 40% of MDS–refractory anemia with excess of blasts (RAEB) and MDS/AML. We performed mouse bone marrow transplantation (BMT) using bone marrow cells transduced with the AML1 mutants. Most mice developed MDS and MDS/AML-like symptoms within 4 to 13 months after BMT. Interestingly, among integration sites identified, Evi1 seemed to collaborate with an AML1 mutant harboring a point mutation in the Runt homology domain (D171N) to induce MDS/AML with an identical phenotype characterized by marked hepatosplenomegaly, myeloid dysplasia, leukocytosis, and biphenotypic surface markers. Collaboration between AML1-D171N and Evi1 was confirmed by a BMT model where coexpression of AML1-D171N and Evi1 induced acute leukemia of the same phenotype with much shorter latencies. On the other hand, a C-terminal truncated AML1 mutant (S291fsX300) induced pancytopenia with erythroid dysplasia in transplanted mice, followed by progression to MDS-RAEB or MDS/AML. Thus, we have developed a useful mouse model of MDS/AML that should help in the understanding of the molecular basis of MDS and the progression of MDS to overt leukemia. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: AML1 and Evi1: coconspirators in MDS/AML? Timothy Graubert Blood 2008 111: 3916-3917. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020